PDCD1 and neoplasm: As described above, Liu et al. validated that combining the APOE inhibitor COG 133 TFA with anti-PD-1 therapy yields a marked synergistic anti-tumor response in TNBC, indicating that targeting APOE can significantly enhance the effectiveness of immune checkpoint inhibitors 29.